158 related articles for article (PubMed ID: 36169564)
1. Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy.
Wakiyama H; Kato T; Furusawa A; Okada R; Inagaki F; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Cancer Immunol Res; 2022 Nov; 10(11):1386-1397. PubMed ID: 36169564
[TBL] [Abstract][Full Text] [Related]
2. Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models.
Fukushima H; Furusawa A; Takao S; Thankarajan E; Luciano MP; Usama SM; Kano M; Okuyama S; Yamamoto H; Suzuki M; Kano M; Choyke PL; Schnermann MJ; Kobayashi H
Oncoimmunology; 2024; 13(1):2370544. PubMed ID: 38915782
[TBL] [Abstract][Full Text] [Related]
3. Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models.
Maruoka Y; Furusawa A; Okada R; Inagaki F; Fujimura D; Wakiyama H; Kato T; Nagaya T; Choyke PL; Kobayashi H
Cancer Immunol Res; 2020 Mar; 8(3):345-355. PubMed ID: 31953245
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
5. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.
Wakiyama H; Furusawa A; Okada R; Inagaki F; Kato T; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Dec; 71(12):2869-2879. PubMed ID: 35445836
[TBL] [Abstract][Full Text] [Related]
6. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
8. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared photoimmunotherapy targeting PD-L1: Improved efficacy by preconditioning the tumor microenvironment.
Inagaki FF; Kano M; Furusawa A; Kato T; Okada R; Fukushima H; Takao S; Okuyama S; Choyke PL; Kobayashi H
Cancer Sci; 2024 Apr; ():. PubMed ID: 38671582
[TBL] [Abstract][Full Text] [Related]
10. Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials.
Okada R; Furusawa A; Vermeer DW; Inagaki F; Wakiyama H; Kato T; Nagaya T; Choyke PL; Spanos WC; Allen CT; Kobayashi H
EBioMedicine; 2021 May; 67():103345. PubMed ID: 33933782
[TBL] [Abstract][Full Text] [Related]
11. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
[TBL] [Abstract][Full Text] [Related]
12. Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.
Nagaya T; Friedman J; Maruoka Y; Ogata F; Okuyama S; Clavijo PE; Choyke PL; Allen C; Kobayashi H
Cancer Immunol Res; 2019 Mar; 7(3):401-413. PubMed ID: 30683733
[TBL] [Abstract][Full Text] [Related]
13. Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response.
Kato T; Fukushima H; Furusawa A; Okada R; Wakiyama H; Furumoto H; Okuyama S; Takao S; Choyke PL; Kobayashi H
Oncoimmunology; 2022; 11(1):2152248. PubMed ID: 36465486
[TBL] [Abstract][Full Text] [Related]
14. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy.
Okada R; Maruoka Y; Furusawa A; Inagaki F; Nagaya T; Fujimura D; Choyke PL; Kobayashi H
Bioconjug Chem; 2019 Oct; 30(10):2624-2633. PubMed ID: 31498995
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
17. Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models.
Maruoka Y; Furusawa A; Okada R; Inagaki F; Fujimura D; Wakiyama H; Kato T; Nagaya T; Choyke PL; Kobayashi H
Vaccines (Basel); 2020 Sep; 8(3):. PubMed ID: 32937841
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
19. Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models.
Kato T; Okada R; Furusawa A; Inagaki F; Wakiyama H; Furumoto H; Okuyama S; Fukushima H; Choyke PL; Kobayashi H
Mol Cancer Ther; 2021 Nov; 20(11):2262-2273. PubMed ID: 34518299
[TBL] [Abstract][Full Text] [Related]
20. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
